Previous 10 | Next 10 |
2023-03-24 12:20:59 ET Gainers: Silvergate Capital Corporation ( SI ) +66% . NaaS Technology ( NAAS ) +36% . Assure Holdings ( IONM ) +21% . Dermata Therapeutics ( DRMA ) +21% . ReNew Energy Global ( RNW ) +20% . GH Research ...
2023-03-24 10:01:43 ET Gainers: Dermata Therapeutics ( DRMA ) +40% . GH Research ( GHRS ) +27% . Vaccitech ( VACC ) +25% . Cosmos Health ( COSM ) +10% . Assure ( IONM ) +6% . Losers: BridgeBio Pharma ( BBIO ) -9%...
2023-03-24 09:39:49 ET Vaccitech press release ( NASDAQ: VACC ): FY GAAP EPS of $0.14. Revenue of $44.7M (+14800.0% Y/Y). For further details see: Vaccitech GAAP EPS of $0.14, revenue of $44.7M
OXFORD, United Kingdom, March 24, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) (the Company, we or us), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases, au...
2023-03-23 10:06:23 ET Gainers: ZyVersa Therapeutics ( ZVSA ) +33% . Aziyo Biologics ( AZYO ) +29% . Generation Bio ( GBIO ) +20% . HTG Molecular Diagnostics ( HTGM ) +16% . scPharmaceuticals ( SCPH ) +15% . Losers:...
VTP-200 was generally well-tolerated with no product-related serious adverse events (SAEs) Interim data showed encouraging initial immunogenicity results, particularly in relation to the E1, E2 and E6 antigens used in VTP-200 HPV001 clinical trial will continue as planned to the 1...
Vaccitech ( NASDAQ: VACC ) appoints industry veteran Nadège Pelletier, Ph.D., as Chief Scientific Officer succeeding Tom Evans, who is retiring but will remain involved as a scientific consultant to the company. Most recently, Dr. Pelletier served at Novarti...
Dr. Pelletier joins leadership team to continue the advancement of Vaccitech’s diverse clinical pipeline and partnerships, bringing more than 15 years’ experience in pharmaceuticals and academia in immunology and infectious diseases Former CSO, Dr. Tom Evans to continu...
OXFORD, United Kingdom, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) today announced that it will host a Key Opinion Leader (KOL) webinar on its SNAPvax™ Platform and application in tolerogenic immunotherapies for celiac disease and other autoimmune diseases on...
Vaccitech press release ( NASDAQ: VACC ): Q3 GAAP EPS of $0.22. Revenue of $6.17M. As of September 30, 2022, cash and cash equivalents were $200.1 million, compared to $214.1 million as of December 31, 2021. For further details see: Vaccitech GAAP EPS of $0.2...
News, Short Squeeze, Breakout and More Instantly...
Vaccitech plc Company Name:
VACC Stock Symbol:
NASDAQ Market:
New Corporate Brand to be Unveiled at AASLD Liver Meeting® 2023 with Interim Data OXFORD, United Kingdom, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS), formerly Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company developing nov...
2023-09-27 06:52:40 ET DENVER, Colo., Sept 27, 2023 ( www.247marketnews.com )- The following stocks are the top performing U.S. stocks over the past week; Vaccitech (NASDAQ: VACC), Siyata Mobile (NASDAQ: SYTA), Soleno Therapeutics (NASDAQ: SLNO), Femasys (NASDAQ: FEMY), Immunovant (NASD...
2023-09-26 07:38:47 ET DENVER, Colo., Sept 26, 2023 ( www.247marketnews.com )- The following stocks are the top performing U.S. stocks over the past week; Vaccitech (NASDAQ:VACC), Lifezone Metals (NYSE:LZM), Globus Maritime Ltd. (NASDAQ:GLBS), Siyata Mobile (NASDAQ:SYTA), ESS Tech (NYSE...